

Monitoring hearing in patients undergoing platinum-based chemotherapy

Submission date 15/02/2022	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 06/04/2022	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 14/02/2024	Condition category Cancer	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Hearing loss is a serious and potentially irreversible side-effect of platinum-based chemotherapy. Current management involves changing or reducing chemotherapy medications if hearing loss is detected. However, early detection is difficult as it currently relies on hearing tests performed in sound-proof booths in Audiology Departments when patients report symptoms of hearing loss or tinnitus (ringing in the ears). This is problematic since arranging such tests adds to the onerous schedule for cancer patients and hearing loss may be only detected after irreversible damage has already occurred. This study aims to investigate the feasibility of:

1. Monitoring hearing more closely throughout chemotherapy treatment in the cancer department itself using soundproof headphones and a tablet-based hearing test that is partly self-administered.
2. Measuring prestin and otolin-1 blood levels as possible markers of impending hearing loss from scheduled blood tests to help predict which patients are likely to develop hearing loss.

Who can participate?

Patients aged 13-40 years treated with platinum-based chemotherapy for bone sarcomas or testicular cancer at the University College London Hospital Macmillan Cancer Centre and St Bartholomew's Hospital will be invited to participate. To be able to take part, patients must have normal hearing at the start of chemotherapy and no history of middle ear disease or previous platinum-based chemotherapy.

What does the study involve?

Patients will receive their cancer treatment as per usual by their own medical teams and have a routine hearing test in the Audiology Department at the beginning and end of their chemotherapy treatment. Patients that have consented to take part in the study will be visited by the audiologist or clinical research practitioner during routine cancer hospital appointments or in the hospital ward. These visits are scheduled at the start of chemotherapy, before and after each chemotherapy cycle and finally 2 weeks after completion of chemotherapy treatment. During the visits, the patients will be asked and supported to undertake the tablet-based hearing test and an automatic hearing test called the distortion production otoacoustic emission (DPOAE) test. During the the first and last visits patients will also be asked to complete quality

of life questionnaires. Those who experience tinnitus will be asked to complete a questionnaire. For patients with sarcoma, from their routine blood tests (taken five times throughout treatment) samples will also be processed for prestin and otolin-1 levels.

What are the possible benefits and risks of participating?

Participants will have their hearing tested more frequently than standard. Of potential benefit, the study may raise earlier concerns about hearing loss, tinnitus, or loud sounds. The research team will support the participants throughout the study and will ensure discussion of hearing test results with the and the medical team throughout.

Where is the study run from?

University College London (UK)

When is the study starting and how long is it expected to run for?

September 2020 to April 2024

Who is funding the study?

Action on Hearing Loss (UK)

Who is the main contact?

Prof. Nish Mehta

evident@ucl.ac.uk

Study website

<https://findastudy.uclh.nhs.uk/#/trial/5fac01f03e717b48f2f2b159>

Contact information

Type(s)

Principal Investigator

Contact name

Prof Nish Mehta

Contact details

91 Gower Street

London

United Kingdom

WC1E 6AB

+44 (0)20 3456 7870

evident@ucl.ac.uk

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

271954

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

126790; CPMS 44553, IRAS 271954

Study information

Scientific Title

Monitoring ototoxicity in patients undergoing treatment with platinum-based chemotherapy for sarcoma and testicular cancer using tablet-based self-administered audiometry and serum biomarkers

Study objectives

The study addresses the following main questions:

1. Is it feasible to conduct out-of-booth tablet-based self-administered audiometry to monitor ototoxicity in patients undergoing treatment with platinum-based chemotherapy for sarcoma and testicular cancer?
2. Can prestin and otolin-1 be used as a biomarker for platinum-based chemotherapy-induced ototoxicity?

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 01/10/2020, London - Camberwell St Giles Research Ethics Committee (Level 3, Block B, Whitefriars, Lewins Mead, Bristol, BS1 2NT, UK;
+44 (0)2071048103; nrescommittee.london-camberwellstgiles@nhs.net), ref :19/LO/1988

Study design

Observational longitudinal study

Primary study design

Observational

Secondary study design

Longitudinal study

Study setting(s)

Hospital

Study type(s)

Diagnostic

Participant information sheet

See additional files

Health condition(s) or problem(s) studied

Platinum-based chemotherapy for sarcoma or testicular cancer

Interventions

Tablet-based self-administered audiometry (TBSA) and distortion product otoacoustic emissions (DPOAE) will be conducted in a quiet room at the hospital. Ambient noise levels in the room will be recorded to ensure they do not exceed 40 dB SPL on average across the tested frequencies (500Hz, 1000Hz, 2000Hz, 4000Hz and 8000Hz). Tablet-based hearing tests that are partly self-administered and DPOAE tests will be performed at baseline, directly before and after each chemotherapy cycle and at a final visit 2-4 weeks after cycle 4. TBSA involves the Shoebox mobile device (iPad) with inbuilt calibrated audiometry. This equipment can be easily moved depending on where the participant is i.e., in the ward, or at their day-care appointment. TBSA includes the test frequencies: 250Hz, 500Hz, 1000Hz, 2000Hz, 3000Hz, 4000Hz, 6000Hz, 8000Hz, 10000Hz, 12500Hz and 16000Hz. The audiologist places the circum-aural headphones onto the patient's ears to ensure that they are correctly placed. Supported by the researcher, the participant uses the iPad screen to demonstrate whether they hear the stimuli. There is a touch "play" button that needs to be dragged into one of two options, the "heard" option or "unheard" which are depicted by green and red symbols respectively. The participant is reminded that not every press of the play button will present a sound i.e., sometimes it will and sometimes it will not. The researcher observes the participant's use of TBSA and records the time taken to complete the TBSA. DPOAE testing with the Otodynamics Otoport Flexi OAE device involves the use of a small soft probe that is inserted into the patient's ear. The patient is advised to remain still and quiet for this test. The total testing time is approximately 30 minutes.

Intervention Type

Device

Pharmaceutical study type(s)

Not Applicable

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Tablet-based self-administered audiometry

Primary outcome measure

Proportion of patients that are compliant with the planned tablet-based self-administered audiometry schedule measured at each scheduled study visit (i.e., baseline, pre-cycle, and post-cycle and at a final visit 2-4 weeks after their final cycle)

Secondary outcome measures

1. Changes in pure-tone and high-frequency hearing levels measured using TBSA from baseline to scheduled study visits at the day before and at day 3 of each chemotherapy cycle and at a final visit 2-4 weeks after the final cycle
2. Changes in distortion product otoacoustic emissions (DPOAE) measured with handheld OAE device, Otoport Flexi OAE, from baseline to scheduled study visits at the day before and at day 3 of each chemotherapy cycle and at a final visit 2-4 weeks after the final cycle
3. Changes in hearing-related quality of life (QoL) measured with the HEAR-QL and Tinnitus Functional Index (TFI) at baseline, pre- and post-cycle (if participant reports a history of tinnitus within 2 weeks of visit), and at a final visit 2-4 weeks after the final cycle. Please note TFI is only measured in adults. There is no equivalent for children and adolescents, therefore will not be

measured in this age group

4. For sarcoma patients only, serum prestin and otoferlin-1 levels measured in blood samples taken at baseline, pre- and post-cycle and at a final visit 2-4 weeks after the final cycle

Overall study start date

01/09/2020

Completion date

30/04/2024

Eligibility

Key inclusion criteria

1. Patients diagnosed with sarcoma (male or female) or testicular cancer (male) and selected for platinum-based chemotherapy
2. Aged between 13 and 40 years
3. Able to provide informed consent
4. Able to understand and cope with the use of headphones and self-administered hearing assessments (as assessed by the researcher at informed consent)
5. No recent history of ear disease, e.g., acute otitis media, otitis media with effusion, middle ear surgery
6. Hearing at screening better than 40 dB across the following frequencies: 0.25, 0.5, 1, 2, 4 and 8 kHz

Participant type(s)

Patient

Age group

Mixed

Sex

Both

Target number of participants

40

Total final enrolment

23

Key exclusion criteria

1. Prior platinum-based chemotherapy within 5 years prior to study cycle 1, day 1
2. Abnormalities of the external or middle ear revealed by otoscopy at screening: otitis externa, otitis media, visible tympanic membrane perforation
3. Conductive hearing loss, a 'true' air-bone gap ≥ 15 dB HL in three or more contiguous frequencies between 0.5, 1, 2, 4 kHz

Date of first enrolment

14/04/2021

Date of final enrolment

31/12/2022

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

The University College Hospital Macmillan Cancer Centre - UCLH Trust

Huntley St

London

United Kingdom

WC1E 6AG

Study participating centre

St Bartholomew's Hospital - Barts Health NHS Trust

W Smithfield

London

United Kingdom

EC1A 7BE

Sponsor information

Organisation

University College London

Sponsor details

c/o Mr Pushpsen Joshi

Joint Research Office

1st Floor Maple House (Suite B)

149 Tottenham Court Road

London

England

United Kingdom

W1T 7DN

+44 (0)20 7679 2000

uclh.randd@nhs.net

Sponsor type

University/education

Website

<http://www.ucl.ac.uk/>

ROR

<https://ror.org/02jx3x895>

Funder(s)

Funder type

Charity

Funder Name

Action on Hearing Loss

Alternative Name(s)

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Results and findings from the study will be submitted and presented at local and inter(national) stakeholders' conferences and published in the scientific literature for the attention of professional and scientific audiences. A summary of the result will be stored with the project at the end of the study.

Intention to publish date

31/07/2024

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are not expected to be made available.

IPD sharing plan summary

Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
-------------	---------	--------------	------------	----------------	-----------------

Participant information sheet	Adults version 1.3	24/08/2020	24/03/2022	No	Yes
Participant information sheet	Young people (aged 13-15 years) version 1.2	24/08/2020	24/03/2022	No	Yes
HRA research summary			28/06/2023	No	No